New applicator for treatment of cellulite; Single treatment tip for body contouring; New applicators for high speed hair removal and skin rejuvenation.
IRVINE, Calif., March 21, 2014 /CNW/ - Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, will showcase technology that shapes the future of aesthetics at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) in Denver March 21-25, 2014.
A leading architect in the global aesthetics industry, Syneron Candela will launch its latest body shaping game changers, the award winning VelaShape® III and the Trio (from recently acquired New Star Lasers, Inc.) for laser assisted lipolysis, endovenous ablation of varicose veins and non-ablative skin rejuvenation.
Syneron Candela will also introduce several new enhancements to the recently launched Velashape III including:
- VSmooth™, a new applicator for temporary reduction in the appearance of cellulite;
- A small tip for the VContour™ applicator designed for the effective treatment of smaller body areas; and
- A uniquely designed large Flat Electrode uniform heating tip that enables significant circumferential reduction in a single treatment.
"Actively responding to the needs of our customers, the VelaShape III is a sophisticated body shaping platform that provides greater efficiency and efficacy, while reducing treatment times and the number of treatments necessary," states Syneron Candela CEO, Amit Meridor. "VelaShape III advances the category of ELOS® based body shaping further than ever before," he adds.
Additionally, the company will showcase:
- A new Gentle Large Spot Delivery System with treatment spot sizes up to 24mm for fast hair removal; and
- The new elos Plus large applicators for faster elos skin rejuvenation and hair removal.
The company will exhibit their robust portfolio of technology solutions aimed at effectively addressing the medical aesthetic needs of today's dermatology practice, including the eTwo™ Station with Sublime and Sublative for facial rejuvenation, the gold standard VBeam for vascular and pigmented lesions and the GentleMAX® Pro for hair removal on all skin types. Also exhibited will be the company's prize-winning skincare line, elure™. This topical solution has transformed the way physicians and consumers treat hyperpigmentation.
"Many of the dermatology industry's greatest minds converge at the AAD," states Meridor. "This meeting provides Syneron Candela a forum to share its innovative solutions and practice support programs while gathering insights on yet to be met aesthetic needs."
Experts will be available at Syneron's Booth #2528 to offer more in depth information on the company's state-of-the-art solutions and to host practice consultations offering additional value to dermatologists who visit Syneron's AAD exhibit.
Syneron Candela is excited to bring the dermatology community a full suite of product offerings that drive aesthetics into the future.
About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Hugo Goldman? Chief Financial Officer ?[email protected]
Syneron Medical – Public Relations ?[email protected]
Please contact Sheila Arway [email protected] to set up an interview with a Syneron executive.
SOURCE: Syneron Medical Ltd.
For further information: